Animal biotechnology is a branch of biotechnology in which molecular biology techniques are used to genetically engineer (i.e. modify the genome of) animals in order to improve their suitability ...
This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...
From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...
Biotech incubator Flagship Pioneering has uncorked its latest company. Lila Sciences is looking to use $200 million in seed funding to develop new advanced artificial intelligence that can power ...
China has captured production of portions of the global biotechnology supply chain to accomplish President Xi Jinping’s goal to “develop effective deterrent against attempts by other countries ...
And like many other young players in the biotechnology business, this one's also still booking sizable losses, adding to investors' general disinterest. What this company lacks in size and profits ...
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer’s disease, according to the federal … ...
In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies from importing goods into China. By Alexandra Stevenson Reporting from ...
First, let’s take a look at the private biotech investments in February 2025, breaking them down by value, location, funding type, and therapeutic subsector. In February 2025, Eikon Therapeutics ...
Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery of molecules to cardiometabolic targets inside cells.
Barclays analyst Gena Wang maintained a Sell rating on Puma Biotechnology (PBYI – Research Report) today and set a price target of $2.00. The company’s shares closed last Friday at $3.58.
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year. No biotech has priced an IPO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback